Creatinine 0 10 0 10 B-clinical_variable
within 11 17 11 17 O
normal 18 24 18 24 O
institutional 25 38 25 38 O
limits 39 45 39 45 O
OR 46 48 46 48 O
creatinine 49 59 49 59 B-clinical_variable
clearance 60 69 60 69 I-clinical_variable
> 70 71 70 71 O
= 71 72 71 72 O
60 73 75 73 75 B-lower_bound
mL 76 78 76 78 I-lower_bound
/ 78 79 78 79 I-lower_bound
min/1.73 79 87 79 87 I-lower_bound
m^2 88 91 88 91 I-lower_bound
for 92 95 92 95 O
subjects 96 104 96 104 O
with 105 109 105 109 O
creatinine 110 120 110 120 B-clinical_variable
levels 121 127 121 127 I-clinical_variable
above 128 133 128 133 O
institutional 134 147 134 147 O
normal 148 154 148 154 O

Eastern 0 7 155 162 B-clinical_variable
Cooperative 8 19 163 174 I-clinical_variable
Oncology 20 28 175 183 I-clinical_variable
Group 29 34 184 189 I-clinical_variable
( 35 36 190 191 I-clinical_variable
ECOG 36 40 191 195 I-clinical_variable
) 40 41 195 196 I-clinical_variable
performance 42 53 197 208 I-clinical_variable
status 54 60 209 215 I-clinical_variable
= 61 62 216 217 O
< 62 63 217 218 O
2 64 65 219 220 B-upper_bound
( 66 67 221 222 O
Karnofsky 67 76 222 231 B-clinical_variable
> 77 78 232 233 O
= 78 79 233 234 O
60 80 82 235 237 B-lower_bound
% 82 83 237 238 I-lower_bound
) 83 84 238 239 O

Hemoglobin 0 10 240 250 B-clinical_variable
> 11 12 251 252 O
= 12 13 252 253 O
8.0 14 17 254 257 B-lower_bound
g 18 19 258 259 I-lower_bound
/ 19 20 259 260 I-lower_bound
dl 20 22 260 262 I-lower_bound
( 23 24 263 264 O
The 24 27 264 267 O
use 28 31 268 271 O
of 32 34 272 274 O
transfusion 35 46 275 286 O
or 47 49 287 289 O
other 50 55 290 295 O
invention 56 65 296 305 O
to 66 68 306 308 O
achieve 69 76 309 316 O
Hemoglobin 77 87 317 327 B-clinical_variable
[ 88 89 328 329 I-clinical_variable
Hgb 89 92 329 332 I-clinical_variable
] 92 93 332 333 I-clinical_variable
> 94 95 334 335 O
= 95 96 335 336 O
8.0 97 100 337 340 O
g 101 102 341 342 O
/ 102 103 342 343 O
dl 103 105 343 345 O
is 106 108 346 348 O
acceptable 109 119 349 359 O
) 119 120 359 360 O

History 0 7 361 368 O
of 8 10 369 371 O
other 11 16 372 377 O
malignancy 17 27 378 388 B-cancer
in 28 30 389 391 O
the 31 34 392 395 O
past 35 39 396 400 B-upper_bound
2 40 41 401 402 I-upper_bound
years 42 47 403 408 I-upper_bound

Human 0 5 409 414 B-chronic_disease
immunodeficiency 6 22 415 431 I-chronic_disease
virus 23 28 432 437 I-chronic_disease
( 29 30 438 439 I-chronic_disease
HIV)-positive 30 43 439 452 I-chronic_disease
patients 44 52 453 461 O
on 53 55 462 464 O
combination 56 67 465 476 B-treatment
antiretroviral 68 82 477 491 I-treatment
therapy 83 90 492 499 I-treatment
are 91 94 500 503 O
ineligible 95 105 504 514 O
because 106 113 515 522 O
of 114 116 523 525 O
the 117 120 526 529 O
potential 121 130 530 539 O
for 131 134 540 543 O
pharmacokinetic 135 150 544 559 B-treatment
interactions 151 163 560 572 I-treatment
with 164 168 573 577 O
ferumoxytol 169 180 578 589 B-treatment

Medical 0 7 590 597 O
contraindications 8 25 598 615 O
to 26 28 616 618 O
esophagectomy 29 42 619 632 B-treatment

Pathologically 0 14 633 647 O
confirmed 15 24 648 657 O
, 24 25 657 658 O
locally 26 33 659 666 O
advanced 34 42 667 675 O
, 42 43 675 676 O
malignancy 44 54 677 687 B-cancer
of 55 57 688 690 I-cancer
the 58 61 691 694 I-cancer
esophagus 62 71 695 704 I-cancer

Patients 0 8 705 713 O
must 9 13 714 718 O
have 14 18 719 723 O
regional 19 27 724 732 B-chronic_disease
adenopathy 28 38 733 743 I-chronic_disease

Patients 0 8 744 752 O
with 9 13 753 757 O
renal 14 19 758 763 B-chronic_disease
insufficiency 20 33 764 777 I-chronic_disease

Positron 0 8 778 786 B-treatment
emission 9 17 787 795 I-treatment
tomography 18 28 796 806 I-treatment
( 29 30 807 808 I-treatment
PET)/CT 30 37 808 815 I-treatment
of 38 40 816 818 O
the 41 44 819 822 O
whole 45 50 823 828 O
- 50 51 828 829 O
body 51 55 829 833 O
or 56 58 834 836 O
skull 59 64 837 842 O
base 65 69 843 847 O
to 70 72 848 850 O
mid 73 76 851 854 O
- 76 77 854 855 O
thigh 77 82 855 860 O

Pregnant 0 8 861 869 B-pregnancy
women 9 14 870 875 B-gender
are 15 18 876 879 O
excluded 19 27 880 888 O
from 28 32 889 893 O
this 33 37 894 898 O
study 38 43 899 904 O
because 44 51 905 912 O
chemoradiotherapy 52 69 913 930 B-treatment
has 70 73 931 934 O
the 74 77 935 938 O
potential 78 87 939 948 O
for 88 91 949 952 O
teratogenic 92 103 953 964 B-treatment
or 104 106 965 967 O
abortifacient 107 120 968 981 O
effects 121 128 982 989 O

Prior 0 5 990 995 O
systemic 6 14 996 1004 B-treatment
chemotherapy 15 27 1005 1017 I-treatment
for 28 31 1018 1021 O
esophageal 32 42 1022 1032 B-cancer
cancer 43 49 1033 1039 I-cancer

Serum 0 5 1040 1045 B-clinical_variable
ferritin 6 14 1046 1054 I-clinical_variable
< 15 16 1055 1056 O
2.0 17 20 1057 1060 B-upper_bound
X 21 22 1061 1062 I-upper_bound
institutional 23 36 1063 1076 I-upper_bound
upper 37 42 1077 1082 I-upper_bound
limit 43 48 1083 1088 I-upper_bound
of 49 51 1089 1091 I-upper_bound
normal 52 58 1092 1098 I-upper_bound

Subjects 0 8 1099 1107 O
who 9 12 1108 1111 O
have 13 17 1112 1116 O
a 18 19 1117 1118 O
contraindication 20 36 1119 1135 O
for 37 40 1136 1139 O
MRI 41 44 1140 1143 B-allergy_name

Subjects 0 8 1144 1152 O
with 9 13 1153 1157 O
cervical 14 22 1158 1166 B-cancer
or 23 25 1167 1169 O
Siewert 26 33 1170 1177 B-cancer
3 34 35 1178 1179 I-cancer
esophageal 36 46 1180 1190 I-cancer
carcinoma 47 56 1191 1200 I-cancer
, 56 57 1200 1201 O
that 58 62 1202 1206 O
are 63 66 1207 1210 O
recommended 67 78 1211 1222 O
by 79 81 1223 1225 O
the 82 85 1226 1229 O
multi 86 91 1230 1235 O
- 91 92 1235 1236 O
disciplinary 92 104 1236 1248 O
tumor 105 110 1249 1254 O
board 111 116 1255 1260 O
to 117 119 1261 1263 O
have 120 124 1264 1268 O
treatment 125 134 1269 1278 B-treatment
other 135 140 1279 1284 O
than 141 145 1285 1289 O
tri 146 149 1290 1293 B-treatment
- 149 150 1293 1294 I-treatment
modality 150 158 1294 1302 I-treatment
chemo 159 164 1303 1308 I-treatment
- 164 165 1308 1309 I-treatment
radiation 165 174 1309 1318 I-treatment
therapy 175 182 1319 1326 I-treatment
( 183 184 1327 1328 I-treatment
RT 184 186 1328 1330 I-treatment
) 186 187 1330 1331 I-treatment
followed 188 196 1332 1340 O
by 197 199 1341 1343 O
esophagectomy 200 213 1344 1357 B-treatment

Subjects 0 8 1358 1366 O
with 9 13 1367 1371 O
evidence 14 22 1372 1380 O
of 23 25 1381 1383 O
iron 26 30 1384 1388 B-chronic_disease
overload 31 39 1389 1397 I-chronic_disease

Total 0 5 1398 1403 B-clinical_variable
bilirubin 6 15 1404 1413 I-clinical_variable
= 16 17 1414 1415 O
< 17 18 1415 1416 O
1.5 19 22 1417 1420 B-upper_bound
X 23 24 1421 1422 I-upper_bound
institutional 25 38 1423 1436 I-upper_bound
upper 39 44 1437 1442 I-upper_bound
limit 45 50 1443 1448 I-upper_bound
of 51 53 1449 1451 I-upper_bound
normal 54 60 1452 1458 I-upper_bound

White 0 5 1459 1464 B-clinical_variable
blood 6 11 1465 1470 I-clinical_variable
cell 12 16 1471 1475 I-clinical_variable
count 17 22 1476 1481 I-clinical_variable
> 23 24 1482 1483 O
= 24 25 1483 1484 O
3.0 26 29 1485 1488 B-lower_bound
K 30 31 1489 1490 I-lower_bound
/ 31 32 1490 1491 I-lower_bound
cu 32 34 1491 1493 I-lower_bound
mm 35 37 1494 1496 I-lower_bound

a 0 1 1497 1498 O
known 2 7 1499 1504 O
history 8 15 1505 1512 O
of 16 18 1513 1515 O
hypersensitivity 19 35 1516 1532 O
to 36 38 1533 1535 O
ferumoxytol 39 50 1536 1547 B-allergy_name

based 0 5 1548 1553 O
on 6 8 1554 1556 O
multi 9 14 1557 1562 O
- 14 15 1562 1563 O
disciplinary 15 27 1563 1575 O
tumor 28 33 1576 1581 B-cancer
board 34 39 1582 1587 O
discussion 40 50 1588 1598 O
, 50 51 1598 1599 O
patients 52 60 1600 1608 O
are 61 64 1609 1612 O
candidates 65 75 1613 1623 O
for 76 79 1624 1627 O
tri 80 83 1628 1631 B-treatment
- 83 84 1631 1632 I-treatment
modality 84 92 1632 1640 I-treatment
treatment 93 102 1641 1650 I-treatment

because 0 7 1651 1658 O
there 8 13 1659 1664 O
is 14 16 1665 1667 O
an 17 19 1668 1670 O
unknown 20 27 1671 1678 O
but 28 31 1679 1682 O
potential 32 41 1683 1692 O
risk 42 46 1693 1697 O
for 47 50 1698 1701 O
adverse 51 58 1702 1709 O
events 59 65 1710 1716 O
in 66 68 1717 1719 O
nursing 69 76 1720 1727 O
infants 77 84 1728 1735 O
secondary 85 94 1736 1745 O
to 95 97 1746 1748 O
the 98 101 1749 1752 O
use 102 105 1753 1756 O
of 106 108 1757 1759 O
ferumoxytol 109 120 1760 1771 B-treatment
as 121 123 1772 1774 O
a 124 125 1775 1776 O
contrast 126 134 1777 1785 O
agent 135 140 1786 1791 O
in 141 143 1792 1794 O
the 144 147 1795 1798 O
mother 148 154 1799 1805 O

breast 0 6 1806 1812 B-cancer
ductal 7 13 1813 1819 I-cancer
carcinoma 14 23 1820 1829 I-cancer
in 24 26 1830 1832 I-cancer
situ 27 31 1833 1837 I-cancer
( 32 33 1838 1839 I-cancer
DCIS 33 37 1839 1843 I-cancer
) 37 38 1843 1844 I-cancer

have 0 4 1845 1849 O
an 5 7 1850 1852 O
allergy 8 15 1853 1860 O
to 16 18 1861 1863 O
gadolinium 19 29 1864 1874 B-allergy_name
( 30 31 1875 1876 I-allergy_name
Gd 31 33 1876 1878 I-allergy_name
) 33 34 1878 1879 I-allergy_name
contrast 35 43 1880 1888 I-allergy_name
material 44 52 1889 1897 I-allergy_name

have 0 4 1898 1902 O
undergone 5 14 1903 1912 O
endoscopic 15 25 1913 1923 B-treatment
biopsy 26 32 1924 1930 I-treatment
with 33 37 1931 1935 O
endoscopic 38 48 1936 1946 B-treatment
ultrasound 49 59 1947 1957 I-treatment
( 60 61 1958 1959 I-treatment
EUS)-proven 61 72 1959 1970 I-treatment
peri 73 77 1971 1975 O
- 77 78 1975 1976 O
esophageal 78 88 1976 1986 O
nodal 89 94 1987 1992 O
involvement 95 106 1993 2004 O

low 0 3 2005 2008 O
- 3 4 2008 2009 O
risk 4 8 2009 2013 O
prostate 9 17 2014 2022 B-cancer
adenocarcinoma 18 32 2023 2037 I-cancer

men 0 3 2038 2041 B-gender
who 4 7 2042 2045 O
are 8 11 2046 2049 O
sexually 12 20 2050 2058 O
active 21 27 2059 2065 O
and 28 31 2066 2069 O
not 32 35 2070 2073 B-contraception_consent
willing 36 43 2074 2081 I-contraception_consent
/ 43 44 2081 2082 I-contraception_consent
able 44 48 2082 2086 I-contraception_consent
to 49 51 2087 2089 I-contraception_consent
use 52 55 2090 2093 I-contraception_consent
medically 56 65 2094 2103 I-contraception_consent
acceptable 66 76 2104 2114 I-contraception_consent
forms 77 82 2115 2120 I-contraception_consent
of 83 85 2121 2123 I-contraception_consent
contraception 86 99 2124 2137 I-contraception_consent

non 0 3 2138 2141 B-cancer
- 3 4 2141 2142 I-cancer
melanomatous 4 16 2142 2154 I-cancer
skin 17 21 2155 2159 I-cancer
cancer 22 28 2160 2166 I-cancer

ongoing 0 7 2167 2174 O
or 8 10 2175 2177 O
active 11 17 2178 2184 B-chronic_disease
infection 18 27 2185 2194 I-chronic_disease

psychiatric 0 11 2195 2206 B-chronic_disease
illness 12 19 2207 2214 I-chronic_disease
/ 19 20 2214 2215 I-chronic_disease
social 20 26 2215 2221 I-chronic_disease
situations 27 37 2222 2232 I-chronic_disease
that 38 42 2233 2237 O
would 43 48 2238 2243 O
limit 49 54 2244 2249 O
compliance 55 65 2250 2260 O
with 66 70 2261 2265 O
study 71 76 2266 2271 O
requirements 77 89 2272 2284 O

radiation 0 9 2285 2294 B-treatment
for 10 13 2295 2298 O
esophageal 14 24 2299 2309 B-cancer
cancer 25 31 2310 2316 I-cancer

severely 0 8 2317 2325 B-chronic_disease
agitated 9 17 2326 2334 I-chronic_disease

subjects 0 8 2335 2343 O
who 9 12 2344 2347 O
have 13 17 2348 2352 O
had 18 21 2353 2356 O
an 22 24 2357 2359 O
allergic 25 33 2360 2368 O
reaction 34 42 2369 2377 O
to 43 45 2378 2380 O
any 46 49 2381 2384 O
intravenous 50 61 2385 2396 B-allergy_name
iron 62 66 2397 2401 I-allergy_name
replacement 67 78 2402 2413 I-allergy_name
product 79 86 2414 2421 I-allergy_name

symptomatic 0 11 2422 2433 B-chronic_disease
congestive 12 22 2434 2444 I-chronic_disease
heart 23 28 2445 2450 I-chronic_disease
failure 29 36 2451 2458 I-chronic_disease

unstable 0 8 2459 2467 B-chronic_disease
angina 9 15 2468 2474 I-chronic_disease
pectoris 16 24 2475 2483 I-chronic_disease

